When dissecting cellular and molecular mechanisms of BCG immunotherapy ... of 6-weekly intravesical instillations of bacillus Calmette–Guerin (BCG), introduced in 1976, has survived to this ...

IBRX), a leading immunotherapy company, today announced compelling new data from its ongoing QUILT 3.032 study. As of November 2024, 100 patients with Bacillus Calmette-Guérin (BCG)-unresponsive ...

Morales’s protocol of 6-weekly intravesical instillations of bacillus Calmette–Guerin (BCG), introduced ... Outcome of BCG immunotherapy of bladder cancer may ultimately depend on imbalance ...

November 19, 2024--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced compelling new data from its ongoing QUILT 3.032 study. As of November 2024, 100 patients with ...

An experimental tuberculosis (TB) vaccine with a dual mission – self-destruction after inducing immunity – improved the design of the Bacillus Calmette-Guérin (BCG) immunotherapy, a vaccine also used ...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced significant progress in its ongoing discussions with the U.S. Food and Drug ...

The phase 3 trial enrolled people with high-risk, non-muscle invasive bladder cancer (NMIBC) who were yet to try Bacillus Calmette-Guérin (BCG), an immunotherapy that has been the standard of ...

This immunotherapy of rescuing BCG with ANKTIVA ... receptor agonist indicated with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive nonmuscle invasive ...

NMIBC BCG Unresponsive Papillary Disease: ImmunityBio is preparing to submit a supplemental Biologics License Application (sBLA) in 2025 for its innovative treatment targeting Bacillus Calmette-Guérin ...

Topline data on a combo including Pfizer’s kinase inhibitor Braftovi point to improved progression-free survival and pave the ...

Bacillus Calmette-Guérin (BCG): A type of immunotherapy used to treat bladder cancer by stimulating the immune system to attack cancer cells.